We have observed that patients affected with a more advanced stage of ovarian cancer—FIGO III had lower expression of GrB-PBMC than those with less severe disease—FIGO I or II (mean 1387 vs. 4513 pg/mg protein, respectively, p = 0.01, t-Student test). The gene discussed is GZMB; the disease is ovarian carcinoma.